Morgan Stanley continues to recommend Allergan Inc. (NYSE:

) with a PT of $85. “Many investors wonder about what is in Allergan Inc.'s pipeline, so we conducted a deep dive analysis on clinical trial websites to try to uncover public information to facilitate analysis,” Morgan Stanley writes. “We were pleased to find that the number of key late stage pipeline readouts (six) over the next nine months matches #s of some major pharma.” Allergan closed Friday at $74.77.